A view on drug resistance in cancer
Explore this paper's citation graph
Summary
A reductionist approach is taken to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures.
- Type
- review
- Published
- 2019-11-01
- Cited by
- 2,376
- References
- 187
- Access
- Open access
- OpenAlex
- https://openalex.org/W2988773550
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:207987518
Keywords
Drug resistance, Cancer, Reductionism, Cancer drugs, Cancer therapy
References
- DYNAMICS OF TUMOR GROWTH. ANL-6723.
- EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.
- A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
- Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies
- Genetic instabilities in human cancers
- Genetic screens in human cells using the CRISPR/Cas9 system
- BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition
- Whole–genome characterization of chemoresistant ovarian cancer
- Free DNA in the serum of cancer patients and the effect of therapy.
- The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
- The importance of dose intensity in chemotherapy of metastatic breast cancer.
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
- Growth curve of an experimental solid tumor following radiotherapy.
- Benefits and Harms of Breast Cancer Screening: A Systematic Review.
- mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
- The clonal evolution of tumor cell populations.
- Seeing the wood for the trees
- Microsatellite alterations in plasma DNA of small cell lung cancer patients
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Cited by
- Vessel co-option and resistance to anti-angiogenic therapy
- Detection of genome-wide low-frequency mutations with Paired-End and Complementary Consensus Sequencing (PECC-Seq) revealed end-repair-derived artifacts as residual errors
- Taxane induces attenuation of the CXCR2/BCL-2 axis and sensitize prostate cancer to platinum-based treatments
- A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer
- Metal-Organic Frameworks for Biomedical Applications.
- Recent advances of smart acid-responsive gold nanoparticles in tumor therapy.
- l-Cysteine decorated nanoscale metal-organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy.
- Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
- Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress
- Perplexing Role of P-Glycoprotein in Tumor Microenvironment
- Copper‐Enriched Prussian Blue Nanomedicine for In Situ Disulfiram Toxification and Photothermal Antitumor Amplification
- Reduction‐Triggered Doxorubicin Delivery by Self‐Assembled Nanospheres of Lipoylated Caffeine
- Breast cancer‐derived exosomes: Tumor progression and therapeutic agents
- Magnetic Measurement and Stimulation of Cellular and Intracellular Structures.
- mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers.
- Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
- Molecular diagnostics in oncology: new trends
- Molecular avenues in targeted doxorubicin cancer therapy.
- Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability
- Overcoming Endocrine Resistance in Breast Cancer
Related papers
- Overcome cancer drug resistance by targeting epigenetic modifications of centrosome
- P53-regulated autophagy and its impact on drug resistance and cell fate
- Cancer drug resistance: a new perspective
- MicroRNAs and cancer drug resistance: over two thousand characters in search of a role
- Drug resistance and combating drug resistance in cancer